StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.75−0.27 (-2.69%)

Close on Nov 16, 2026Market cap $645.19MP/E –Yield –

Bicara Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Bicara Therapeutics's enterprise value was $197.00M on Nov 11, 2026, against $723.44M a year earlier. Over the last 2 years it ranged from -$215.28M to $1.41B, with a median of $427.06M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$197.00M-68.7%
2025Dec 31, 2025$628.96M+47.3%
2024Dec 31, 2024$427.06M–

More Bicara Therapeutics figures

See a number that looks wrong?